Biocodex fully acquires TargEDys

TargEDys and Biocodex have been partners since 2019, when Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became the distributor of TargEDys’ leading PreciBiomic, Symbiosys Satylia®, in France, then in Portugal and Poland. Now, the French family company has acquired 100% of TargEDys’ shares, to consolidate the group’s strong ambition in the Microbiome and accelerate TargEDys’ development globally.

Symbiosys Satylia® is a precision probiotic supplement based on Hafnia alvei HA4597®with a deeply characterized mechanism of action at the molecular level: it increases the feeling of fullness thanks to the ability of the protein ClpB to mimic the satiety hormone alpha-MSH. Its efficacy was demonstrated in a clinical trial involving 230 overweight adults. It is a new, natural, safe, and effective solution to weight management and a multi-award winner – including Best Probiotic of the Year 2021 by the internationally-recognized NutraIngredients Awards.

“This integration within Biocodex will be an enabler of TargEDys’ mission, to bringing the Microbiome to the heart of healthcare, and increase awareness on its unique strains portfolio with scientifically proven efficacy”,

stated Aurore Matton, General Manager of TargEDys

With the acquisition of TargEDys, we strengthen our ambition to become the leader in Microbiota care. We are happy to welcome a like-minded team with the common drive of  improving the health and well-being of women and men worldwide through microbiome-based innovations and education,

says Nicolas Coudurier, Chief Executive Officer of Biocodex.

About Biocodex – “Healthcare with passion and conviction”

Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,600 employees, Biocodex generated net revenues of above €500 million in 2022, including 35% in France and 65% internationally. The group is present in 115 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.

More information on

About TargEDys® – “From Probiotics to PreciBiomics”

TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions for the control of appetite through microbiome interventions. The company is the fruit of over 15 years of research on the microbiota conducted within academic laboratories. The team developed and started the commercialization of a first product based on the PreciBiomic, or precision probiotic strain Hafnia alvei HA4597™ which efficacy in weight and appetite has been clinically demonstrated. Targedys® develops a product portfolio focusing on overweight, undernutrition and mental health, all based on the concept of PreciBiomic strains backed by a molecular mechanism of action and in vivo studies.

More information on